Eli Lilly and Company (LLY) — Aktienbewertung · KI-Wettbewerbsvorteilsanalyse

↑Patent Protection on Key Drugs

Lilly benefits from strong patent protection on drugs like Trulicity and Mounjaro. This exclusivity allows for premium pricing and market share dominance before generics enter.

↑Established Brand Reputation in Diabetes Care

Lilly has cultivated a strong brand in diabetes, fostering physician and patient loyalty. This reputation provides a competitive edge in a growing market.

↑Pipeline of Innovative Therapies

Lilly's robust pipeline, particularly in Alzheimer's and obesity, offers future growth potential. Successful drug launches will further solidify their market position.

↓Patent Expirations and Generic Competition

Loss of exclusivity on key drugs will significantly impact revenue. Lilly must successfully launch new products to offset these losses and maintain growth.

↓Clinical Trial Failures and Regulatory Hurdles

Drug development is inherently risky, and clinical trial failures are common. Regulatory delays or rejections can significantly impact pipeline value.

↓Pricing Pressure and Reimbursement Challenges

Increasing pressure from payers to lower drug prices could erode profitability. Changes in reimbursement policies could limit access to Lilly's therapies.